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Imaging endogenous macrophage 
iron deposits reveals a metabolic 
biomarker of polarized tumor 
macrophage infiltration and 
response to CSF1R breast cancer 
immunotherapy
Avigdor Leftin1, Nir Ben-Chetrit2,4, Johanna A. Joyce  2,5 & Jason A. Koutcher1,3
Iron deposits are a phenotypic trait of tumor-associated macrophages (TAMs). Histological iron 
imaging and contrast-agent free magnetic resonance imaging (MRI) can detect these deposits, but 
their presence  in human cancer, and correlation with immunotherapeutic response is largely untested. 
Here, primarily using these iron imaging approaches, we evaluated the spatial distribution of polarized 
macrophage populations containing high endogenous levels of iron in preclinical murine models 
and human breast cancer, and used them as metabolic biomarkers to correlate TAM infiltration 
with response to immunotherapy in preclinical trials. Macrophage-targeted inhibition of the colony 
stimulating factor 1 receptor (CSF1R) by immunotherapy was confirmed to inhibit macrophage 
accumulation and slow mammary tumor growth in mouse models while also reducing hemosiderin 
iron-laden TAM accumulation as measured by both iron histology and in vivo iron MRI (FeMRI). Spatial 
profiling of TAM iron deposit infiltration defined regions of maximal accumulation and response to the 
CSF1R inhibitor, and revealed differences between microenvironments of human cancer according to 
levels of polarized macrophage iron accumulation in stromal margins. We therefore demonstrate that 
iron deposition serves as an endogenous metabolic imaging biomarker of TAM infiltration in breast 
cancer that has high translational potential for evaluation of immunotherapeutic response.
In most cancers, macrophage infiltration is linked to negative clinical outcomes such as poor survival, metastatic 
dissemination, and evasion of anti-tumor immune mechanisms1–4. Major efforts are underway to understand 
the function of macrophage infiltrates in the tumor microenvironment in order to develop new treatments such 
as immunotherapies that target macrophages and inhibit these deleterious outcomes. To support these efforts, 
there is an increasing need for macrophage biomarkers and imaging approaches that allow for the localization of 
the targeted macrophage populations according to metabolic phenotype or function and measurement of their 
response to therapy. Histological methods are useful for quantification of macrophage behavior, but in vivo char-
acterization is not possible, and definition of specific phenotypic properties such as polarization status or metab-
olism can be difficult to generalize from selective biopsy due to tissue intrinsic aspects of macrophage function 
and the heterogeneous nature of the tumor microenvironment5,6. In vivo approaches such as positron emission 
tomography (PET) can provide information about tumor macrophage presence, but repeated imaging is limited 
due to the accumulation of radioactive dose, and resolution of infiltrating macrophages is also limited by current 
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technology7,8. As an in vivo imaging tool, magnetic resonance imaging (MRI) can be used to map many metabolic 
pathways associated with cancer including glycolysis9,10, the tricarboxylic acid cycle11, phospholipid and ATP 
metabolism12,13, dependencies on perfusion and hypoxia14, pH15, and oxidation/reduction balance16. Despite this 
arsenal of anatomical and functional molecular protocols, these non-invasive approaches are usually not able 
to resolve and assign spatial differences in metabolism to specific immune cell populations within the tumor. 
This is because the metabolic properties of these populations are often obscured as they share similar metabolic 
pathways to the cancer cells, have smaller relative population sizes, and more heterogeneous spatial distributions 
compared to the bulk of the tumor17. Given the available resolution of most metabolic MRI techniques this leads 
to an average representation of the spatial distribution of metabolites, often reflecting just the dominant cellular 
population, i.e. the cancer cells, in the metabolic images.
In order to enable the imaging of macrophages according to their metabolic status, we sought to identify 
metabolic pathways that exhibit higher specificity for these populations rather than cancer cells or other cellular 
species. Iron metabolism, the processes by which uptake, storage, and re-export of iron takes place, is conserved 
in most mammalian cells18. However, macrophages in particular are known to play a central role in systemic 
homeostasis of iron according to their unique genetic program that enables them to handle high metabolic flux 
of this micronutrient systemically and in the tumor microenvironment19–21. In this iron-regulating role, mac-
rophages can exhibit a unique phenotypic trait, namely the accumulation of aggregates comprised of iron known 
as hemosiderin22. Recently, we identified endogenous hemosiderin iron deposition as a putative pan-tissue bio-
marker of TAMs by using clinical iron-sensitive MRI methods (FeMRI) and Prussian blue iron histology with-
out contrast agents to detect accumulated iron in hemosiderin-laden macrophages (HLMs) of murine prostate, 
breast, and metastatic cancer models23,24. Technically, high-iron concentration FeMRI pixel regions and Prussian 
blue positive regions indicate the location of macrophage iron deposits that sets them apart from other lower 
concentration bio-iron sources such as blood due to the physical magnetic and chemical properties of the solid 
iron stores25–33. Similar high-resolution MRI and histological iron imaging approaches can also be used to identify 
macrophage targets in cancer but traditionally require intravenous injections of iron nanoparticle contrast agents 
that rely on macrophage phagocytosis rather than metabolism in a manner similar to many PET probes34,35. 
However, caveats of the nanoparticle-enhanced MRI and histological techniques include off-target delivery fol-
lowing from the enhanced permeability and retention effect contributed by highly vascularized leaky tumors that 
reduces specificity for the macrophage deposits36, and the nanoparticles themselves can induce polarization of 
macrophages that can potentially bias the metabolic function and the therapeutic response of the targeted popula-
tions37–39. By recognizing the tendency of macrophages to metabolically accumulate hemosiderin—which gener-
ates high-iron contrast akin to that produced using iron nanoparticle injections40 —microscopic deposits of these 
cells can be quantified in terms of their abundance and spatial distribution by MRI and histology without contrast 
agents according to their innate iron metabolism. While these prior studies associated HLMs with TAMs and 
therefore suggest that they can be used as probes of TAM infiltration to gauge efficacy of immune therapy, here we 
define the spatial correlations of these metabolically-unique TAM infiltrates with immunotherapy response, and 
prospectively characterize their distribution in human breast cancer using histological iron imaging in order to 
support the translation of such combination metabolic iron imaging and therapy approaches to the clinic.
Results
Spatial profiling of tumor macrophage iron deposits with iron imaging. Endogenous FeMRI 
methods are increasingly favored over the use of invasive biopsy using Prussian blue iron imaging for meas-
urement of non-heme iron concentrations in liver, heart, and brain26–28,41–44. While these methods mitigate the 
sampling bias introduced by selective biopsy, they conventionally rely on whole organ averages of cellular iron 
loading, and therefore neglect spatial heterogeneity indicative of TAM infiltration. We rationalized that we could 
also use FeMRI and correlative Prussian blue histology to detect, resolve, and quantify the spatial distributions of 
localized TAM iron deposits in breast cancer tumors by addressing spatial heterogeneity of cellular iron deposits 
through utilization of image analysis algorithms that enable the automatic detection, quantification, and local-
ized mapping of HLM deposits in the iron images40. As proof-of-concept, we directly compared histological 
sections stained for iron using Prussian blue that is specific for HLMs (Fig. 1a), with iron maps generated by ex 
vivo FeMRI-microscopy (Fig. 1b) of co-registered tissue sections obtained from an orthotopic TS1 breast cancer 
model used commonly in TAM research whose tumors are promoted under control of the murine mammary 
tumor virus which drives expression of the mammary gland specific polyoma virus middle T-antigen (MMTV-
PyMT)45–49. Iron+ TAMs were determined to be the dominant species generating distinct high-iron pixel clusters 
in the MMTV-PyMT tumor cross-sections as comparison of Prussian Blue stained macrophage (Fig. 1c) and red 
blood cells (Fig. 1d), another candidate for contributing to iron contrast because of their heme cargo, showed 
they do not stain for Prussian blue iron and thus contribute only to low FeMRI contrast, further corroborating 
the specificity of the method for HLMs23. We then interrogated the spatial distribution of the HLMs in the his-
tological and FeMRI iron maps to compare these measurements as a score of TAM infiltration. Analysis of the 
histological (Fig. 1e), and MRI images (Fig. 1f) for high concentrations of iron yielded maps of the iron contain-
ing TAMs. The histological iron deposits and FeMRI pixel clusters were then graphed as a function of position in 
the tumor (% infiltration, Fig. 1g), and the radial infiltration profiles of the histological deposits and MRI clusters 
were found to be the same (Fig. 1h, p > 0.05). This confirmed the equivalence between the HLM measurements 
by FeMRI and histology, and further provided a novel means to map the spatial distribution of the HLM deposits 
according to metabolic status with cellular sensitivity.
Correlation between immunotherapeutic CSF1R inhibitor response and polarized iron deposit 
accumulation. To then further establish these TAM iron deposits as immunotherapy targets, we initiated 
preclinical CSF1R (colony-stimulating factor-1 receptor) inhibitor (BLZ945) trials in murine breast cancer 
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models. This receptor kinase inhibitor blocks the interaction between the cytokine colony stimulating factor 1 
(CSF1) that mediates macrophage accumulation in tumors via signaling with its receptor CSF1R50,51. The drug 
has been shown to have the primary immunological effect of inhibiting the accumulation of TAMs in tumors, 
making it an excellent candidate for testing the iron imaging approaches, and it has the coincident therapeutic 
effect of slowing the growth of some breast, cervical, brain, and other cancers48,52–55. Cell-line derived TS1 and 
99LN MMTV-PyMT tumors orthotopically implanted in the mammary fat pads of their respective syngeneic 
FVB/N and C57BL6 hosts were studied. Treatment with the small molecule CSF1R inhibitor BLZ945 was ini-
tiated when tumors reached approximately 100 mm3 in the TS1 and 99LN models. Treatment continued until 
control tumors reached or exceeded 1 cm3 measured by caliper to establish pre-treatment and endpoint imaging 
time points, and significant tumor growth inhibition was observed in both models with CSF1R inhibition by 
these endpoints (Fig. 2a, p < 0.001–p < 0.0001). Subsequent measurement of the tumor volumes made by MRI in 
the imaging studies of the control and BLZ945 treated TS1 (Fig. 2b,c) and 99LN models (Fig. 2d,e) recapitulated 
the reductions in tumor volumes established by the initial pilot trials where TS1 tumor volumes were 51% of 
Figure 1. Imaging and spatial profiling of tumor macrophage iron deposits ex vivo with iron MRI (FeMRI) and 
Prussian blue iron histology. (a) Representative Prussian blue iron histology of MMTV-PyMT TS1 mammary 
tumor cross-section. Scale bar 2.5 mm. Expansion shows iron+ macrophage deposits. Expansion scale bar 
50 μm. (b) Representative ex vivo FeMRI of MMTV-PyMT TS1 mammary tumor cross-section. Scale bar 
2.5 mm. Expansion shows high-iron pixel clusters. Expansion scale bar 50 μm. (c) Representative Prussian 
Blue iron histology of tumor associated macrophages (TAM), and (d) red blood cells (RBC). Note iron+ 
macrophages and iron− RBCs. (e) Iron deposit mask from Prussian blue histology. Scale bar 2.5 mm. (f) High-
iron FeMRI cluster mask. Scale bar 2.5 mm. (g) Infiltration mapping using radial decile region rake sampling 
overlaid on high-iron MRI cluster mask. Scale bar 2.5 mm. 4x expansion shows high-iron FeMRI clusters and 
decile boundaries. (h) Infiltration profile showing number of histological iron deposits from Prussian blue (PB) 
and high-iron FeMRI pixel clusters (FeMRI) as a function of percent (%) infiltration into the MMTV-PyMT 
TS1 mammary tumors. (mean + s.e.m. n = 3 tissue cross-sections, n.s. p > 0.05 Kolmogorov-Smirnov test).
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controls, and the drug also limited the growth of the 99LN model tumors to approximately 34% of the untreated 
groups (Fig. 2f, p < 0.01).
To then characterize the primary immunological effect of the CSF1R inhibitor on TAM accumulation as has 
been done in previous studies in MMTV-PyMT models with the BLZ945 drug and others45,48, whole tumors from 
the TS1 and 99LN models were collected at imaging endpoints and single-cell suspensions were prepared from 
the homogenates. Fluorescence staining of the cells for live CD45+Ly6c−Ly6g−CD11b+F4/80+ TAMs was then 
performed and the frequency of these cells was quantified by flow cytometry. Treatment with BLZ945 reduced the 
frequency of TS1 TAMs (Fig. 2g,h), and similarly 99LN models also exhibited reductions in TAMs (Fig. 2i,j) in 
accord with the previous studies of the inhibitor, thereby providing further preclinical validation for our imaging 
studies. Overall the CSF1R immune therapy lowered the frequency of TAMs with respect to total CD45+ cells in 
the tumors significantly with levels of BLZ945 treated TAM fraction by approximately 30% of the control levels in 
both TS1 and 99LN groups (Fig. 2k, p < 0.001– p < 0.01).
Figure 2. Validation of CSF1R immunotherapy effects on tumor growth and TAM accumulation in PyMT-
MMTV breast cancer models. (a) Murine breast tumor models were established by orthotopic mammary 
fat pad injections and measured by caliper in TS1 and 99LN models during administration of the CSF1R 
inhibitor BLZ945 (200 mg/kg). Arrows indicate start of BLZ945 treatment (mean ± s.e.m. n = 5 mice/group, 
***p < 0.001, ****p < 0.0001, 2-way ANOVA with Tukey’s multiple comparison test). Representative first-echo 
images from MGE MRI experiments made at study endpoints in control and BLZ945 treated (b,c) TS1 and 
(d,e) 99LN MMTV-PyMT models. (f) Pre-treatment and endpoint tumor volumes measured by MRI in the 
CSF1R inhibitor trials. (mean + s.e.m., n = 8 mice/group, **p < 0.01, two-tailed unpaired students t-test). Flow 
cytometry panels of TAMs (live CD45+Ly6c−Ly6g− cells gated on CD11b+F4/80+ cells) obtained from control 
and BLZ945 treated (g,h) TS1, and (i,j) 99LN tumors. (k) TAM frequency with respect to total CD45+ myeloid 
cells in the TS1 and 99LN CSF1R inhibitor trials (mean + s.e.m. n = 4 mice/group, **p < 0.01, ***P < 0.001, 
two-tailed unpaired students t-test).
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In order to quantify the response of iron+ TAMs to the BLZ945 inhibitor, we performed Prussian blue histol-
ogy specific for the TAM iron deposits beside CD68 macrophage histology as a general marker of TAMs. First, 
digitized images of paraffin-embedded whole axial cross-sections of the tumor collected at CSF1R trial endpoints 
were analyzed by counting all TAMs according to their CD68 staining to measure general response to the CSF1R 
inhibitor. Reduced numbers of CD68+ infiltrating macrophages were found in both the TS1 (Fig. 3a,b) and 99LN 
cohorts (Fig. 3c,d) confirming previous studies of this inhibitors effects on TAM accumulation in MMTV-PyMT 
models45. Overall, CD68+ macrophages were lower by approximately 42% in the TS1 model and 55% in the 99LN 
model following BLZ945 treatment (Fig. 3e, p < 0.01) generally recapitulating the reductions in TAMs meas-
ured by flow cytometry in the trials. Histological assessments of HLMs using Prussian blue iron staining were 
Figure 3. CD68 immunofluorescence and Prussian blue imaging of macrophage iron deposits in MMTV-
PyMT murine breast cancer models of CSF1R immunotherapy. Representative CD68 macrophage 
immunofluoresent imaging in control and BLZ945 treated (a,b) TS1, and (c,d) 99LN tumors. Scale bar 250 µm 
(e) Absolute counts of CD68+ macrophages per mm2 MMTV-PyMT tumor cross-section in BLZ945 CSF1R 
inhibitor trials (mean + s.e.m. n = 4 mice/group, **p < 0.01, two-tailed unpaired students t-test). Representative 
iron staining using Prussian blue iron histochemistry in control and BLZ945 treated MMTV-PyMT (f,g) TS1, 
and (h,i) 99LN tumors. Scale bar 250 µm (j) Absolute counts of iron+ macrophages per mm2 tumor cross-
section in the CSF1R inhibitor trials (mean + s.e.m. n = 4 mice/group, ***p < 0.001, two-tailed unpaired 
students t-test).
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performed in the same manner as CD68 histology. TS1 tumors in the syngeneic FVB/N background exhibited 
numerous HLM deposits consisting of colonies of iron+ TAMs found largely in stromal margins of the paraf-
fin embedded tumor cross-sections (Fig. 3f), and treatment with BLZ945 reduced the number of these cellular 
species (Fig. 3g). The iron+ TAMs were relatively fewer in the 99LN models, but were still detected in the digital 
image analysis of the Prussian blue iron-stained 99LN tumors (Fig. 3h), and these iron deposits were also lowered 
with BLZ945 treatment (Fig. 3i). Administration of the CSF1R inhibitor reduced iron+ TAM accumulation by 
approximately 50% in the TS1 models and 85% in the 99LN models (Fig. 3j, p < 0.001), again corroborating the 
primary effect of the CSF1R inhibitor on TAM accumulation, and further indicating that this drug also effects 
iron containing TAM populations.
Macrophage accumulation in tumors fulfills both inflammatory and anti-inflammatory roles, but little is 
known about the polarization and CSF1R status of iron+ TAMs. To investigate the polarization status of these 
macrophage subpopulations, Prussian blue iron-stained histological sections (Fig. 4a,b) were re-stained using 
multiplexed immunofluorescence for M1-like (Fig. 4c,d, pro-inflammatory, AIF1; allograft inflammatory 
factor-1), M2-like (Fig. 4e,f, anti-inflammatory, CD206; mannose receptor), and CSF1R receptor (Fig. 4g,h) 
markers in the TS1 and 99LN models. Controlling for the primary inhibitory effect on the accumulation of iron+ 
populations, fields containing the iron+ TAMs in control tumors and fields still containing iron deposits following 
BLZ945 treatment were identified in the registered tumor cross-sections in order to quantify the co-positivity of 
the iron+ TAMs as a function of M1-like, M2-like, and CSF1R status in these localized regions. Counts of these 
macrophage populations in the TS1 and 99LN tumors (Fig. 4k,l) showed that TS1 tumors had relatively higher 
numbers of macrophages expressing polarization markers and CSF1R compared with the 99LN model in accord 
with the cell counts made independently of polarization status. The CSF1R inhibitor BLZ945 did not greatly effect 
these general populations, though a small reduction of CD206+ macrophage was observed in the TS1 deposit 
regions (p < 0.05). To specifically assess changes in polarization status of the iron+ macrophages with BLZ945 
treatment, the fractions of iron+ macrophage subpopulations expressing M1-like, M2-like, and mixed M1- and 
M2-like markers were calculated as a function of the total iron+AIF1+, iron+CD206+ and iron+AIF1+CD206+ 
populations in the TS1 (Fig. 4m) and 99LN models (Fig. 4n). Similarly, the iron+AIF1+, iron+CD206+ and 
iron+AIF1+CD206+ populations were also assessed for CSF1R positivity calculated as a fraction of total iron+CS-
F1R+AIF1+, iron+CSF1R+CD206+ and iron+CSF1R+AIF1+CD206+ macrophages present (Fig. 4o,p). This 
analysis revealed that while the iron+ populations were found co-localized with AIF1 and CD206 polarization 
markers as well as CSF1R, the fraction of these iron+ M1-like and iron+ M2-like species and their CSF1R+ coun-
terparts in these iron deposit regions were largely unaffected by the CSF1R inhibitor except for small differences 
in iron+AIF1+CD206+, iron+CSF1R+AIF1+ and iron+CSF1R+AIF1+ CD206+ populations in the fields assessed 
(p < 0.05). This histological analysis indicates that polarization of the iron+ populations, and general populations 
overall is largely unaffected by the CSF1R inhibitor, and also indicated that the HLMs were not significantly 
biased towards a given polarization state as they were frequently co-localized with multiple markers.
Iron imaging of macrophage tumor infiltration in CSF1R inhibitor trials. In vivo contrast-agent 
free FeMRI was then used to quantify macrophage iron deposits of the MMTV-PyMT models in the BLZ945 tri-
als, and correlate their detection with the CSF1R inhibitor’s primary immunotherapeutic effects on macrophage 
accumulation and tumor growth. FeMRI images were quantified using image-processing algorithms demon-
strated above in the ex vivo analysis. Control and BLZ945 treated MMTV-PyMT mammary tumors exhibited 
high-iron pixel clusters indicative of macrophage iron deposits in both the TS1 (Fig. 5a,b) and 99LN (Fig. 5c,d) 
models. High-iron pixel clusters found in BLZ945 treated tumors were approximately 37% of control levels in 
both models (Fig. 5e p < 0.01) supporting the flow cytometry and histological measurements as shown in Figs 2 
and 3. Tumor growth and accumulation of FeMRI clusters were positively correlated in both TS1 (Fig. 5f) and 
99LN models (Fig. 5g), and immunotherapeutic response was indicated by a reduction in tumor growth and 
inhibition of FeMRI cluster accumulation.
Counts of the high-iron FeMRI pixel clusters and HLM deposits found in histological Prussian blue iron 
images were also analyzed as a function of position in order to establish spatially-resolved scores of immuno-
therapeutic response (Fig. 6a–d). The scores of the FeMRI clusters (Fig. 6e,f) and HLM deposits (Fig. 6g,h) both 
showed higher levels of TAMs at the stromal margins of the tumors with decreasing numbers of iron containing 
cells found towards the tumor core where less macrophage infiltration generally occurs. Treatment with BLZ945 
resulted in overall lower levels of the iron containing regions throughout the tumor cross-sections. The clusters 
measured by FeMRI and HLM deposits measured by Prussian blue histology were most affected at the outer 
margins of the tumors by the CSF1R therapy as indicated by the significant reductions observed over these 
regions (p < 0.05-p < 0.0001). This establishes that contrast-agent free in vivo FeMRI can detect and map mac-
rophage iron deposits in a similar manner to ex vivo iron histology, and that using FeMRI and iron histology dur-
ing CSF1R immunotherapy provides measurements of TAM infiltration correlated with the regions of maximal 
immunotherapeutic response. Thus, iron serves as a novel metabolic biomarker indicating response to immuno-
therapy treatment that can be monitored in vivo using non-invasive MRI technology.
Prospective survey of polarized macrophage iron deposit infiltration in human breast cancer. 
The eventual clinical translation of iron as a metabolic biomarker for macrophage detection and its combination 
with CSF1R immunotherapy largely depends on whether iron deposits are detectable in human breast cancer. 
Therefore, prospective surveys of histological samples containing regions of human carcinoma in situ and invasive 
carcinoma were performed by staining paraffin-embedded sections with the Prussian blue method to identify 
non-heme iron deposits specific to HLMs. Iron deposits were detected in the stromal margins of carcinoma in 
situ (CIS, Fig. 7a), and were also detected at stromal boundaries of invasive carcinoma (INV, Fig. 7b). In regions 
densely populated by cancer cells in highly invasive carcinoma where stromal margins were not evident these 
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deposits were absent (Fig. 7c). Profiling of HLM deposit infiltration as a function of position across regions 
indicative of CIS (Fig. 7d) and INV where the HLMS are present (Fig. 7e) further indicated significant spatial dif-
ferences between the HLMs in these breast cancer microenvironments. Similar to the murine spatial infiltration 
profiles, human HLMs were more abundant at the outer stromal margins of the tumors, and in situ carcinoma 
was found to exhibit higher numbers of infiltrating HLMs compared with the margins of the invasive carcinoma 
tumor microenvironments (Fig. 7f, p < 0.01-p < 0.0001). This confirmed the association of macrophage iron 
Figure 4. Immunofluorescent and Prussian blue imaging of macrophage iron deposit polarization and CSF1R 
status in MMTV-PyMT murine breast cancer models of CSF1R immunotherapy. Representative registered 
fields centered on TAM iron deposits in MMTV-PyMT TS1 and 99LN tumors stained for iron with Prussian 
blue (a,b), allograft inflammatory factor-1 (AIF1, M1-like, c,d), mannose receptor (CD206, M2-like, e,f), colony 
stimulating factor 1 receptor (CSF1R, g,h) and the combined immunofluorescent channels(i,j). Note fields 
of control tumors are shown, but are representative of both control and BLZ945 treated groups. Each field is 
200 µm × 200 µm. Scale bar 50 µm. Blue arrows indicate location of iron+ macrophage in 99LN field. Number 
(#) of AIF1+, CSF1R+, CD206+ and iron+ macrophages detected per field for control and BLZ945 treated 
(k) TS1 and (l) 99LN MMTV-PyMT mammary tumor models (mean + s.e.m. n = 20 fields for TS1 control 
and BLZ945, n = 20 fields for 99LN control and n = 7 fields for 99LN BLZ945, *p < 0.05, Mann-Whitney 
test). Fraction of total iron+AIF1+, iron+CD206+, and iron+AIF1+CD206+ macrophages detected per field 
in control and BLZ945 treated groups for (m) TS1 and (n) 99LN mammary tumor models. Fraction of total 
iron+CSF1R+AIF1+, iron+CSF1R+CD206+ and iron+CSF1R+AIF1+CD206+ macrophages detected per field 
in control and BLZ945 treated groups for (o) TS1 and (p) 99LN mammary tumor models (mean + s.e.m. 
n = 20 fields for TS1 control, n = 20 fields TS1 BLZ945, n = 20 fields for 99LN control and n = 7 fields for 99LN 
BLZ945, *p < 0.05, Mann-Whitney test).
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deposits with human breast cancer, and shows that while they are commonly found in the tumor-stroma bound-
aries of both cancer subtypes, they are more prominently observed in the in situ pathologies where the stromal 
margins are better defined compared to invasive carcinoma where such margins can be less evident. As in situ 
carcinoma is thought to precede the emergence of invasive carcinoma, these findings support the translational 
value of using iron as an early cancer imaging biomarker of TAMs.
The iron+ TAMs in the human cancers were further tested for polarization and CSF1R status using multi-
plexed immunofluorescence imaging methods as we performed in the murine CSF1R inhibitor trials56. The CIS 
and INV fields stained for Prussian blue iron+ HLMs (Fig. 8a,b) were re-stained for inflammatory M1-like mac-
rophages (Fig. 8c,d; AIF1), anti-inflammatory M2-like macrophages (Fig. 8e,f; CD206), and the CSF1R recep-
tor (Fig. 8g,h) in order to determine the co-positivity of iron with these markers (Fig. 8i,j). The total numbers 
of macrophages were assessed in fields centered on HLM deposits in the stromal margins of the CIS and INV 
regions. The AIF1+, CSF1R+, and CD206+ macrophages were significantly different in the CIS and INV regions 
(Fig. 8k) and corresponded to higher numbers of pro-inflammatory AIF1+ cells in INV fields (p < 0.0001), 
while CSF1R+ (p < 0.05), CD206+ (p < 0.01), and iron+ macrophages (p < 0.001) were significantly lower in 
these same regions. To quantify the association of the iron+ macrophages with these markers the fraction of 
iron+AIF1+, iron+CD206+, iron+AIF1+CD206+ macrophage were calculated as a function of the total polarized 
iron+ TAM population (Fig. 8l), and similarly these iron+ populations were assessed for co-positivity with the 
CSF1R marker (Fig. 8m) to determine whether the iron+ TAMs in these fields express this receptor to further 
motivate later immunotherapeutic interventions using CSF1R inhibitors. Overall, significantly higher fractions 
of iron+AIF1+ (p < 0.01) and iron+AIF1+CD206+ (p < 0.0001) macrophages were found in CIS microenviron-
ments, while iron+CD206+ markers were statistically the same in CIS and INV locations (p > 0.05). Additionally, 
the calculation of the fraction of the iron+AIF1+ and iron+CD206+ populations with CSF1R indicated that 
significantly more iron+CSF1R+AIF1+ (p < 0.001) and iron+CSF1R+CD206+ (p < 0.001) macrophages were 
present in CIS fields and iron+CSF1R+AIF1+CD206+ populations were largely the same in the CIS and INV 
Figure 5. In vivo iron MRI (FeMRI) of murine macrophage iron deposits and correlation between immune 
and therapeutic CSF1R inhibitor response. Representative in vivo FeMRI axial cross sections of the mammary 
tumors are shown in control and BLZ945 treated (a,b) TS1, and (c,d) 99LN models. Scale bar 2.5 mm. 
Expansions show high-iron pixel clusters. Scale bar 200 µm. (e) Number (#) of high-iron FeMRI pixel clusters 
in the TS1 and 99LN tumors in the CSF1R inhibitor trials (mean + s.e.m. n = 8 mice/group, **p < 0.01 two-
tailed unpaired students t-test). Linear correlations between high-iron FeMRI clusters and tumor volumes in 
the control(ο) and BLZ945-treated(•) (f) TS1 and (g) 99LN MMTV-PyMT tumor models (n = 8 mice/group, R2 
and correlation p-value from linear Pearson correlation are shown).
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microenvironments (p > 0.05). Thus, we demonstrate that TAMs in the human breast cancer microenviron-
ments differ in their phenotype, and that iron accumulation occurs in polarized TAMs of human breast cancer. 
Interestingly, the iron+ macrophages in both cancer types were associated with polarization markers as well as 
CSF1R, however, the fraction of these polarized iron+ subpopulations was biased towards M1-like and CSF1R+ 
status in the CIS regions, but also frequently exhibited mixed phenotypic character in both settings. In the context 
of our novel iron imaging approaches, this indicates that while macrophage polarization is an important immu-
nological factor in both murine and human cancers, the number of iron+ macrophages itself can serve as a TAM 
imaging biomarker that is sensitive to microenvironment and stage of the cancer with high-potential for in vivo 
detection by MRI.
Discussion
The accumulation of hemosiderin iron in tumor-associated macrophages enables the imaging of these cells 
in heterogeneous tumor microenvironments according to localized differences in iron metabolism. In earlier 
studies we reported that iron deposits occur in the stromal margins of murine mammary tumors and pros-
tate cancers using histological imaging and in vivo FeMRI23,24,40. Recently, these iron deposits have also been 
detected in the stromal margins of non-small cell lung cancer tumors37, and we have also shown them to be 
present in lung and brain metastases23. In the current study we confirmed that such TAM iron deposits are pres-
ent in multiple MMTV-PyMT breast cancer models, they are correlated with response to CSF1R breast cancer 
immunotherapy, and we demonstrated that the spatial infiltration and accumulation of the TAM iron deposits 
is a factor that is conserved in murine and human breast cancer and differentiates between human breast cancer 
microenvironments.
From an in vivo imaging standpoint our novel measurements also serve to further establish FeMRI as a unique 
approach for the detection and monitoring of immune cell response to cancer immunotherapy. Alternative MRI 
approaches label macrophages using injections of iron nanoparticles34,35,57, and injected radiolabelled nanoparti-
cles used in PET imaging can also be used to measure macrophage during immunotherapy trials8,58. Our imaging 
studies are set-apart from these contrast agent-dependent techniques as we do not use contrast agent injections. 
Figure 6. Spatial scores of murine tumor macrophage infiltration in CSF1R immune therapy trials from iron 
MRI and Prussian blue iron histology. (a) In vivo iron MRI (FeMRI) of MMTV-PyMT mammary tumor. Scale 
bar 1 mm. Expansion shows high-iron pixel clusters. Scale bar 100 µm. (b) Binary high-iron pixel cluster mask 
from FeMRI of MMTV-PyMT tumor cross-section. Scale bar 1 mm. Concentric rake region of interest grid 
overlay used to profile clusters is shown. Expansion shows detected clusters and concentric counting grid. 
Scale bar 200 µm. (c) Prussian blue iron stained cross-section of MMTV-PyMT tumor showing the rake grid 
overlay used to score the iron deposits. Scale bar 1 mm. (d) Expansion showing deposit, i.e. colony of iron+ 
macrophages. Scale bar 200 µm. Infiltration profiles of high-iron clusters from FeMRI in control and BLZ945-
treated (e) TS1 and (f) 99LN MMTV-PyMT models (mean + s.e.m. n = 8 mice/group, *p < 0.05, ***p < 0.001, 
****p < 0.0001, 2-way ANOVA with Sidak’s multiple comparison test). Iron+ macrophage deposit infiltration 
profiles from Prussian blue histology in control and BLZ945-treated (g) TS1 and (h) 99LN MMTV-PyMT 
models (mean + s.e.m. n = 4 mice/group, *p < 0.05, ***p < 0.001, ****p < 0.0001, 2-way ANOVA with Sidak’s 
multiple comparison test).
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We instead capitalize on the high physiological innate iron metabolism of macrophages that results in the phe-
notypic storage of solid deposits of iron that is readily validated using Prussian blue iron histochemistry of the 
TAM iron deposits. These magnetic deposits give rise to characteristic high-iron FeMRI pixel contrast that reveals 
their infiltration in the tumor microenvironment where they fulfill obligate roles in iron storage and recycling21. 
Although our reliance on endogenous iron stores to image TAMs is potentially restricted because we only detect 
those macrophages engaged in iron handling roles, our previous findings and current studies showing HLMs 
in the different MMTV-PyMT backgrounds as well as human cancers support the feasibility of using the iron 
imaging approaches to image them, and supports the combination of this form of endogenous cell-tracking with 
immunotherapeutic trials targeting macrophage in the clinic.
While we focus on iron as a primary biomarker of tumor macrophages in this contribution, TAMs are also rec-
ognized to adopt so-called polarization phenotypes that are closely associated with their role in immune response 
and communication to other immune cells such as T-cells that is critical for immunotherapeutic efficacy48,53. 
These multifactorial polarization states reflect the stage of immune response, progression of primary tumor and 
metastasis growth, as well as the microenvironment and tissue in which they are found6. We discovered that mac-
rophage iron deposits are found more prevalently at the stromal margins of tumors in murine models and human 
breast cancers suggesting that iron is another microenvironmental factor influencing macrophage phenotype 
and spatial distribution. However, when we investigated the polarization status of the macrophage iron deposits 
we found them to be associated with various phenotypic polarization markers, and they were often co-localized 
Figure 7. Spatial scores of iron deposits from Prussian blue histology in human breast cancer. Prussian Blue 
iron histochemistry shows the presence of iron deposits in (a) stromal margins of carcinoma in situ (CIS) 
and (b) invasive carcinoma (INV, blue arrows). No iron deposits were associated with (c) invasive carcinoma 
exhibiting poorly defined stromal margins. Scale bar 200 µm. Expansions of boxes in (a–c) shown below. Scale 
bar 40 µm. Concentric rake region of interest grid overlay used to profile HLMs in (d) CIS and (e) INV fields. 
Scale bar 100 µm. (f) Iron+ macrophage (HLM) infiltration profiles from Prussian blue histology in CIS and 
INV fields. (mean + s.e.m. n = 5 fields/cancer subtype, **p < 0.01, ****p < 0.0001, 2-way ANOVA with Sidak’s 
multiple comparison test).
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Figure 8. Immunofluorescent and Prussian blue imaging of human macrophage iron deposit polarization and 
CSF1R status. Representative registered fields of human carcinoma in situ (CIS) and invasive carcinoma where 
iron deposits are found (INV) stained for iron with Prussian blue (a,b), allograft inflammatory factor-1 (AIF1, 
c,d), mannose receptor (CD206, e,f), colony stimulating factor 1 receptor (CSF1R, g,h) and the combined 
immunofluorescent channels (i,j). Each field is 200 µm × 200 µm. Scale bar 50 µm. (k) Number (#) of AIF1+, 
CSF1R+, CD206+ and iron+ macrophages detected per CIS and INV field. (mean+s.e.m. n=18 fields for 
CIS, n=9 fields for INV, *p < 0.05, ***p < 0.001, ****p < 0.0001, Mann-Whitney test). (l) Fraction of total 
iron+AIF1+, iron+CD206+, and iron+AIF1+CD206+ macrophages detected per CIS and INV field. (m) Fraction 
of total iron+CSF1R+AIF1+, iron+CSF1R+CD206+, and iron+CSF1R+AIF1+CD206+ macrophages detected 
per CIS and INV field (mean+s.e.m. n=18 fields for CIS, n=10 fields for INV, **p < 0.01, ***p < 0.001, 
****p < 0.0001, Mann-Whitney test).
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with macrophage markers indicating mixed polarization character, rather than adopting a single polarization 
state. While the current studies do not address the functional significance of such polarization states in the con-
text of their role in signaling to other immune cells, it is evident due to their clear association with iron that they 
serve a primary functional role in iron metabolism. In this regard it can be speculated that iron+ macrophages 
are primed to fill M1-like inflammatory functions where they sequester iron to shield it from depletion due to 
hemorrhage or pathogen, as well as function in M2-like wound-healing roles where they serve as stores of iron to 
sustain cellular proliferation of the microenvironmental milieu during tissue repair19. This scenario is supported 
by our observations of the differences in iron+ macrophage of in situ and invasive human cancers. Here, more 
iron+ macrophages were found in earlier cancer stages suggesting that these macrophages avidly stored iron 
during initial inflammatory immune response to the cancer. Similarly, in advanced cancers reduced numbers of 
iron-containing TAMs presumably reflects the depletion of stromal macrophage iron stores in order to fuel the 
cancer’s malignant outgrowth as it has been proposed that cancer cells have a pronounced dependence on iron 
metabolism that serves to co-opt this critical micronutrient from other cellular species in the tumor microenvi-
ronment60,61. In this context, the iron+ deposits can themselves be used as specific histological and in vivo bio-
markers of TAM infiltration which varies with immune status and cancer stage without the need for assessment 
of tissue-dependent polarization.
Immune therapies such as the small molecule inhibitors of macrophage colony stimulating factor 1 receptor 
(CSF-1R) including BLZ945 and PLX3397, as well as antibodies directed against this receptor have been shown 
to reduce the accumulation of TAMs in preclinical models and achieve therapeutic gains as monotherapy and 
in combination with other therapies48,52. We confirmed the primary immunotherapeutic effects of the CSF1R 
inhibitor in the MMTV-PyMT mammary tumor models by demonstrating that the drug achieves reduction 
in macrophage accumulation together with tumor growth inhibition. We also confirmed that the iron+ mac-
rophages express CSF1R in murine and human breast cancers supporting their role as targets of these immuno-
therapies. Indeed, inhibition of macrophage accumulation by CSF1R therapy resulted in significant reductions of 
iron-laden macrophage deposits in the orthotopic MMTV-PyMT models. Therefore, these studies validated the 
immunotherapeutic effect of the drug in the breast tumor models, further identified the iron-laden macrophage 
populations as responsive to the CSF1R immunotherapy, and confirm their CSF1R status for future therapeutic 
targeting in human cancer.
Cancer therapies targeting iron metabolism under current investigation have sought to either achieve ther-
apeutic gains by iron loading using nanoparticle theranostic injections, or by causing iron depletion with iron 
chelators24,37,39,62. In the current studies we identify another means of targeting cellular iron for therapy. By capi-
talizing on the observation that iron deposits are restricted to TAMs, we demonstrate that CSF1R inhibition that 
directly targets TAMs can also be used to indirectly prevent accumulation of TAM iron deposits. As our murine 
investigations and surveys of human breast cancers confirm the presence of these cells and characterize their spa-
tial dependencies, targeting the iron deposits using CSF1R inhibitors and spatially monitoring them using iron 
imaging has notable potential value as a translational therapeutic cancer imaging strategy. Further applications of 
this approach include diseases such as iron overload disorder, neurodegeneration, inflammation, and hemorrhage 
where iron deposits may be present and their detection, mapping, and subsequent therapeutic reduction can be 
desirable41,42,59,63.
Conclusions
In sum we identified iron deposition as a metabolic biomarker of macrophage infiltration in murine and human 
breast cancer that identifies responsive polarized TAM populations to CSF1R immunotherapy using histological 
and in vivo iron imaging together with preclinical cancer research approaches. While the current studies support 
our ability to image polarized TAMs according to iron status in breast cancer, and suggest that iron deposits 
are associated with specific types of cancer, given the diverse types of human breast cancers encountered in the 
clinic, further histopathology will be required to more completely characterize the association of the deposits with 
the myriad immunological markers involved in immunotherapeutic studies, as well as correlate their accumu-
lation with cancer stage, and clinical outcome. Also, though these findings support the translation of the FeMRI 
approaches to human breast cancer, and our detection of iron deposits in human cancer strongly supports the 
feasibility of this approach, further imaging validations will ultimately determine whether the approaches pre-
sented here in preclinical models will find their niche in clinical cancer imaging and immunotherapy trials in the 
future. Therefore, these demonstrations support such future studies that seek to image immune cells and harness 
their innate functional and metabolic dependencies for therapy.
Methods
Magnetic resonance imaging. MRI was performed on a 7T/30 cm horizontal bore Bruker Biospec MRI 
system (Bruker Biospin Corp.) with a custom-built 30 mm inner-diameter transmit-receive quadrature radio-fre-
quency coil.
Iron MRI. 2D multi-gradient echo (MGE) relaxometry pulse sequence was used with the follow-
ing parameters: TR/TE 1.2 s/3 ms × 16 echos, in vivo spatial resolution 0.1 mm × 0.1 mm × 1 mm, ex vivo 
0.05 mm × 0.05 mm × 0.5 mm, RF flip angle 60°, and each spatial encoding phase encode acquisition was gated on 
the animal’s respiratory cycle. The first image of the gradient-echo series was used as reference images shown in 
the figures and overlays, and all images shown and analyzed correspond to axial mid-section slices of the tumors.
Aqueous solutions of iron(III) nitrate (Fisher Scientific) were used as standards for iron concentration meas-
ured at 7T as described in refs23,24,40. The T2* values for these solutions was determined by pixel-wise monoexpo-
nential fitting of the MGE images using Fiji64, and the linear relation between the relaxation rate R2* = 1/T2* and 
known iron concentrations was found and subsequently used to generate parametric maps of iron concentration. 
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Quantification of high-iron FeMRI clusters was conducted by binary stratification with respect to the median of 
the concentration range of the iron maps followed by counting the frequency of the high-iron pixel clusters with 
the Fiji Analyze Cluster tool. Infiltration profiles of the high-iron clusters were generated by measuring them as 
a function of position according to a concentric ring pattern generated with the Fiji ROI Manager tool macros.
Animal procedures. All animal studies were approved by the MSKCC IACUC committee and performed in 
accordance with their guidance and regulations.
In vivo MRI. Mice were anesthetized with 1–3% isoflurane in O2 gas, and respiration was monitored during 
all imaging sessions.
Primary tumor models. Female 6 week-old FVB/N or C57BL6 mice underwent orthotopic mammary fat 
pad injection of 1 × 106 syngeneic TS1 MMTV-PyMT or 99LN tumor cell lines grown and collected using stand-
ard tissue culture conditions and suspended in a 50% solution of Matrigel and saline (BD Bioscience). Endpoint 
was defined as when the control cohorts average tumor size reached approximately 1 cm3 determined by caliper, 
MRI, or veterinary staff inspection notice.
CSF1R inhibitor administration. The CSF1R inhibitor BLZ945 (Novartis) was administered by oral 
gavage (200 mg kg−1 in captisol vehicle, 5×/week). Dosing commenced once tumors exceeded approximately 
100 mm3 and continued until control cohorts average tumor size reached approximately 1 cm3 determined by 
caliper, MRI, or veterinary staff inspection notice.
Flow cytometry. Tumor-bearing mice at endpoint were perfused with 20 mL of PBS prior to mammary 
tumor retrieval at endpoint. Tumors were washed once in PBS and enzymatically digested for 45 minutes into 
a single cell suspension using a tumor dissociation kit (Miltenyi Biotec). Cell suspensions were filtered twice 
through 70 μm cell strainers, and Fc-blocked for 30 minutes on ice (1:50; clone 2.4G2, BD Bioscience). Cells were 
then immunostained using antibodies (BioLegend) for CD45 (1:400; clone: 30-F11), Ly-6C (1:400; clone HK1.4), 
Ly-6G (1:400; clone 1A8), CD11b (1:200; clone M1/70), and F4/80 (1:250; clone BM8) for 45  minutes on ice. Cells 
were then washed twice in PBS and suspended in FACS-buffer (2% FBS in PBS) containing DAPI (2.5 μg/mL; 
Invitrogen) for exclusion of dead cells. TAMs were identified as DAPI−CD45+Ly6C−Ly6G−CD11b+F4/80+ cells, 
and frequency of TAMs was determined from counts in the F4/80+CD11b+ flow cytometry gates with respect to 
total live CD45+ cells using FCS Express (De Novo Software).
Histology. Cross-sections from the PBS-perfused MMTV-PyMT tumors were sliced at the axial tumor mid-
point and fixed in 4% PFA for 24 hours at 4 °C, and then washed with H2O and re-suspended in 70% ethanol (Fisher 
Scientific). Human tissue sections donated to the Molecular Cytology Core Facility by the Pathology Department 
were acquired under MSKCC Institutional Review Board informed consent and provided for the study without any 
unique patient identifiers except diagnosis. They were fixed in 10% neutral buffered formalin. All tissues were paraf-
fin embedded and 5 μm sections cut onto glass slides and coverslipped prior to histological quantification.
The Prussian blue histochemical detection of iron(III) was performed by standard methods using 30 minute 
staining of de-parrafinized slides in equal parts 10% potassium ferricyanide (Fisher Scientific) and 10% hydro-
chloric acid (Fisher Scientific) followed by nuclear-fast red counter-staining for 30 minutes.
The immunofluorescent detection of CD68 (Boster, cat# PA1518, 5 ug/ml, 5 hours) was performed using  
standard Discovery XT processor protocols and reagents (Ventana Medical Systems) with biotinylated goat 
anti-rabbit antibodies (Vector Labs, cat#PK6101, 60 minutes) at 1:200 dilution, and visualized with Tyramide 
Alexa Fluor A546 (Invitrogen, cat# T20933) and DAPI (Sigma Aldrich, cat# D9542, 5 µg/ml) prepared according 
to manufacturer’s instructions with predetermined dilutions.
Multiplex immunofluorescent stainings were performed as previously described56. Prussian blue stained slides 
were differentiated, and sections were then sequentially incubated with anti-CSF1R (Santa Cruz, cat#sc-692, 
0.5 µg/ml, 5 hours) and biotinylated goat anti-rabbit IgG (Vector labs, cat#PK6101, 60 minutes) at 1:200 dilution, 
anti-CD206 (Abcam, cat#ab64693, 1 µg/ml, 5 hours) and biotinylated goat anti-rabbit IgG (Vector labs, cat#PK6101, 
60 minutes) at 1:200 dilution, and finally anti-AIF1 (Wako, cat#019–19741, 0.5 µg/ml, 5 hours) and biotinylated goat 
anti- rabbit IgG (Vector labs, cat#PK6101, 60 minutes) at 1:200 dilution. The detection was performed successively 
for each of the antibodies using streptavidin-HRP D (part of DABMap kit, Ventana Medical Systems) followed by 
incubation with Tyramide Alexa 488 (Invitrogen, cat# B40953) for CSF1R, Tyramide Alexa 647 (Invitrogen, cat# 
B40958) for CD206, and Tyramide Alexa 568 (Invitrogen, cat# T20948) for AIF1, and  DAPI (Sigma Aldrich, cat# 
D9542, 5 µg/ml) prepared according to manufacturer instruction with predetermined dilutions.
Histological sections were digitized with a Mirax scan system and read with Panoramic Viewer 
(3DHISTECH). Images were first visually inspected for quality and then processed to remove background fluo-
rescence and provide maximal signal for binary spot counting performed over whole cross-sections or selected 
fields from exported images using Fiji according to staining or immunofluorescent labeling. Deposits of iron 
containing macrophages and their infiltration profiles were quantified from the Prussian Blue histology using the 
Fiji Analyze Cluster tool and ROI Manager macro tools as described in refs.23,24,40 and also applied to the FeMRI 
data. Evaluation of iron+ macrophage polarization phenotype in murine and human tissue was conducted by 
co-registering Prussian blue and triple-stained immunofluorescent images, identification of 200 µm × 200 µm 
fields centered on iron deposits, and performing exhaustive binary counts made of the iron+ cells as a function of 
AIF, CD206 and CSF1R positivity in Fiji. Fractional populations were calculated by dividing the total counts of a 
given set of co-localized macrophage markers by the sum of the markers being compared, for example M2-like 
polarization of iron containing macrophage was calculated by dividing the iron+CD206+ population by the sum 
of iron+AIF1+, iron+CD206+, and iron+AIF1+CD206+ populations.
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Statistics. Statistical tests are indicated in the figure legends when performed and significance is determined 
as p < 0.05 in all analyses. All statistical analyses were performed with GraphPad Prism 7 (GraphPad Software).
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